Biotech and Pharmaceutical
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Market Summary

Company Profiles


Research Store

Biotech Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, is in Phase 2 development in chronic pain patients. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

 Key Statistics

Ownership: Public

Web Site: Nektar Therapeutics (CA)
Employees: 421
Symbol: NKTR

 Company News
Nektar Therapeutics (CA) (NKTR) Reports Positive Preclinical Data For Two Oncology Programs At 2014 American Association for Cancer Research 4/9/2014 8:06:43 AM    More...
Nektar Therapeutics (CA) (NKTR) Reports Fourth Quarter And Year-End 2013 Financial Results 2/27/2014 6:30:05 AM    More...
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The Fourth Quarter And Year-End Of 2013 On Wednesday, February 26, 2014, After Close Of U.S.-Based Financial Markets 2/20/2014 6:20:21 AM    More...
Nektar Therapeutics (CA) (NKTR) Prices Public Offering Of Common Stock 1/23/2014 11:07:05 AM    More...
Nektar Therapeutics (CA) (NKTR) Announces Public Offering Of 8,500,000 Shares Of Common Stock 1/23/2014 10:47:58 AM    More...
Nektar Therapeutics (CA) (NKTR) Presents Positive Clinical Data From A Phase 1 Study Of Etirinotecan Pegol (NKTR-102) In Combination With 5-Flourouracil/Leucovorin At The 2014 Gastrointestinal Cancers Symposium 1/20/2014 6:23:58 AM    More...
Nektar Therapeutics (CA) (NKTR) Release: Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis For BEACON Pivotal Phase 3 Clinical Study In Patients With Metastatic Breast Cancer 1/14/2014 11:05:15 AM    More...
Nektar Therapeutics (CA) (NKTR) Release: First Subjects Dosed In Phase 1 Clinical Study Of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker To Treat Neuropathic Pain 1/14/2014 10:51:58 AM    More...
Nektar Therapeutics (CA) (NKTR)' President And CEO, Howard W. Robin, To Present At The 32nd Annual J.P. Morgan Healthcare Conference In San Francisco, CA 1/9/2014 6:28:48 AM    More...
Nektar Therapeutics (CA) (NKTR) Release: New Drug Application For Naloxegol Accepted By FDA 11/19/2013 11:29:55 AM    More...